590 related articles for article (PubMed ID: 29498923)
1. IKZF1
Stanulla M; Dagdan E; Zaliova M; Möricke A; Palmi C; Cazzaniga G; Eckert C; Te Kronnie G; Bourquin JP; Bornhauser B; Koehler R; Bartram CR; Ludwig WD; Bleckmann K; Groeneveld-Krentz S; Schewe D; Junk SV; Hinze L; Klein N; Kratz CP; Biondi A; Borkhardt A; Kulozik A; Muckenthaler MU; Basso G; Valsecchi MG; Izraeli S; Petersen BS; Franke A; Dörge P; Steinemann D; Haas OA; Panzer-Grümayer R; Cavé H; Houlston RS; Cario G; Schrappe M; Zimmermann M; ;
J Clin Oncol; 2018 Apr; 36(12):1240-1249. PubMed ID: 29498923
[TBL] [Abstract][Full Text] [Related]
2. The clinical impact of IKZF1 deletions in paediatric B-cell precursor acute lymphoblastic leukaemia is independent of minimal residual disease stratification in Nordic Society for Paediatric Haematology and Oncology treatment protocols used between 1992 and 2013.
Olsson L; Ivanov Öfverholm I; Norén-Nyström U; Zachariadis V; Nordlund J; Sjögren H; Golovleva I; Nordgren A; Paulsson K; Heyman M; Barbany G; Johansson B
Br J Haematol; 2015 Sep; 170(6):847-58. PubMed ID: 26018335
[TBL] [Abstract][Full Text] [Related]
3. Frequency and prognostic impact of PAX5 p.P80R in pediatric acute lymphoblastic leukemia patients treated on an AIEOP-BFM acute lymphoblastic leukemia protocol.
Jung M; Schieck M; Hofmann W; Tauscher M; Lentes J; Bergmann A; Stelter M; Möricke A; Alten J; Schlegelberger B; Schrappe M; Zimmermann M; Stanulla M; Cario G; Steinemann D
Genes Chromosomes Cancer; 2020 Nov; 59(11):667-671. PubMed ID: 32592278
[TBL] [Abstract][Full Text] [Related]
4. Refining risk stratification in paediatric B-acute lymphoblastic leukaemia: Combining IKZF1
Liu HC; Huang YJ; Jaing TH; Wu KH; Chen SH; Wang SC; Yeh TC; Hsiao CC; Chang TK; Yen HJ; Huang FL; Lin PC; Hou JY; Sheen JM; Liao YM; Chang TY; Chen YC; Chiou SS; Yang CP; Pui CH; Liang DC; Shih LY
Br J Haematol; 2024 Apr; 204(4):1344-1353. PubMed ID: 38479427
[TBL] [Abstract][Full Text] [Related]
5. Tumor suppressors BTG1 and IKZF1 cooperate during mouse leukemia development and increase relapse risk in B-cell precursor acute lymphoblastic leukemia patients.
Scheijen B; Boer JM; Marke R; Tijchon E; van Ingen Schenau D; Waanders E; van Emst L; van der Meer LT; Pieters R; Escherich G; Horstmann MA; Sonneveld E; Venn N; Sutton R; Dalla-Pozza L; Kuiper RP; Hoogerbrugge PM; den Boer ML; van Leeuwen FN
Haematologica; 2017 Mar; 102(3):541-551. PubMed ID: 27979924
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of IKZF1 deletions and IKZF1
Braun M; Pastorczak A; Sędek Ł; Taha J; Madzio J; Jatczak-Pawlik I; Wypyszczak K; Matysiak M; Derwich K; Lejman M; Kazanowska B; Szczepański T; Kowalczyk JR; Mlynarski W;
Hematol Oncol; 2022 Aug; 40(3):430-441. PubMed ID: 35118711
[TBL] [Abstract][Full Text] [Related]
7. The prognostic value of IKZF1
Kicinski M; Arfeuille C; Grardel N; Bakkus M; Caye-Eude A; Plat G; Ferster A; Uyttebroeck A; De Moerloose B; Rohrlich P; Suciu S; Bertrand Y; Cavé H
Pediatr Blood Cancer; 2023 Jun; 70(6):e30313. PubMed ID: 36971444
[TBL] [Abstract][Full Text] [Related]
8. The correlation between Pax5 deletion and patients survival in Iranian children with precursor B-cell acute lymphocytic leukemia.
Moafi A; Zojaji A; Salehi R; Najafi Dorcheh S; Rahgozar S
Cell Mol Biol (Noisy-le-grand); 2017 Aug; 63(8):19-22. PubMed ID: 28886309
[TBL] [Abstract][Full Text] [Related]
9. Combination of minimal residual disease on day 15 and copy number alterations results in BCR-ABL1-negative pediatric B-ALL: A powerful tool for prediction of induction failure.
Baghdadi H; Soleimani M; Zavvar M; Bahoush G; Poopak B
Cancer Genet; 2024 Apr; 282-283():27-34. PubMed ID: 38183785
[TBL] [Abstract][Full Text] [Related]
10. The Genomic Landscape of PAX5, IKZF1, and CDKN2A/B Alterations in B-Cell Precursor Acute Lymphoblastic Leukemia.
Ou Z; Sherer M; Casey J; Bakos HA; Vitullo K; Hu J; Friehling E; Gollin SM; Surti U; Yatsenko SA
Cytogenet Genome Res; 2016; 150(3-4):242-252. PubMed ID: 28214896
[TBL] [Abstract][Full Text] [Related]
11. Ikaros (IKZF1) alterations and minimal residual disease at day 15 assessed by flow cytometry predict prognosis of childhood BCR/ABL-negative acute lymphoblastic leukemia.
Volejnikova J; Mejstrikova E; Dörge P; Meissner B; Zimmermannova O; Svojgr K; Stanulla M; Cario G; Schrappe M; Stary J; Hrusak O; Trka J; Fronkova E
Pediatr Blood Cancer; 2013 Mar; 60(3):420-7. PubMed ID: 22997141
[TBL] [Abstract][Full Text] [Related]
12. High frequency of intermediate and poor risk copy number abnormalities in pediatric cohort of B-ALL correlate with high MRD post induction.
Singh M; Bhatia P; Trehan A; Varma N; Sachdeva MS; Bansal D; Jain R; Naseem S
Leuk Res; 2018 Mar; 66():79-84. PubMed ID: 29407587
[TBL] [Abstract][Full Text] [Related]
13. Copy number alterations in B-cell development genes, drug resistance, and clinical outcome in pediatric B-cell precursor acute lymphoblastic leukemia.
Steeghs EMP; Boer JM; Hoogkamer AQ; Boeree A; de Haas V; de Groot-Kruseman HA; Horstmann MA; Escherich G; Pieters R; den Boer ML
Sci Rep; 2019 Mar; 9(1):4634. PubMed ID: 30874617
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of copy number alterations in adolescent and adult patients with precursor B acute lymphoblastic leukemia enrolled in PETHEMA protocols.
Ribera J; Morgades M; Zamora L; Montesinos P; Gómez-Seguí I; Pratcorona M; Sarrà J; Guàrdia R; Nomdedeu J; Tormo M; Martínez-Lopez J; Hernández-Rivas JM; González-Campos J; Barba P; Escoda L; Genescà E; Solé F; Millá F; Feliu E; Ribera JM;
Cancer; 2015 Nov; 121(21):3809-17. PubMed ID: 26194343
[TBL] [Abstract][Full Text] [Related]
15. Copy number abnormality of acute lymphoblastic leukemia cell lines based on their genetic subtypes.
Tomoyasu C; Imamura T; Tomii T; Yano M; Asai D; Goto H; Shimada A; Sanada M; Iwamoto S; Takita J; Minegishi M; Inukai T; Sugita K; Hosoi H
Int J Hematol; 2018 Sep; 108(3):312-318. PubMed ID: 29786757
[TBL] [Abstract][Full Text] [Related]
16. IGH@ translocations, CRLF2 deregulation, and microdeletions in adolescents and adults with acute lymphoblastic leukemia.
Moorman AV; Schwab C; Ensor HM; Russell LJ; Morrison H; Jones L; Masic D; Patel B; Rowe JM; Tallman M; Goldstone AH; Fielding AK; Harrison CJ
J Clin Oncol; 2012 Sep; 30(25):3100-8. PubMed ID: 22851563
[TBL] [Abstract][Full Text] [Related]
17. Deletion of CDKN2A/B is associated with inferior relapse free survival in pediatric B cell acute lymphoblastic leukemia.
Kathiravan M; Singh M; Bhatia P; Trehan A; Varma N; Sachdeva MS; Bansal D; Jain R; Naseem S
Leuk Lymphoma; 2019 Feb; 60(2):433-441. PubMed ID: 29966470
[TBL] [Abstract][Full Text] [Related]
18. IKZF1 deletion is associated with a poor outcome in pediatric B-cell precursor acute lymphoblastic leukemia in Japan.
Asai D; Imamura T; Suenobu S; Saito A; Hasegawa D; Deguchi T; Hashii Y; Matsumoto K; Kawasaki H; Hori H; Iguchi A; Kosaka Y; Kato K; Horibe K; Yumura-Yagi K; Hara J; Oda M;
Cancer Med; 2013 Jun; 2(3):412-9. PubMed ID: 23930217
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of genetic alterations in children with first bone marrow relapse of childhood B-cell precursor acute lymphoblastic leukemia.
Krentz S; Hof J; Mendioroz A; Vaggopoulou R; Dörge P; Lottaz C; Engelmann JC; Groeneveld TW; Körner G; Seeger K; Hagemeier C; Henze G; Eckert C; von Stackelberg A; Kirschner-Schwabe R
Leukemia; 2013 Feb; 27(2):295-304. PubMed ID: 22699455
[TBL] [Abstract][Full Text] [Related]
20. [The value of minimal residual disease and IKZF1 deletion for predicting prognosis in adult patients with B-cell acute lymphoblastic leukemia].
Deng SY; Ou JW; Huang ZC; Chen JJ; Cai ZH; Liu QF; Zhou HS
Zhonghua Xue Ye Xue Za Zhi; 2024 Mar; 45(3):257-263. PubMed ID: 38716597
[No Abstract] [Full Text] [Related]
[Next] [New Search]
